Tag: combination therapies

  • Combination Therapies in Pharma – Removing the Antitrust Roadblock

    Combination Therapies in Pharma – Removing the Antitrust Roadblock

    This month, the Belgian Competition Authority (BCA) published guidance on information exchange between pharmaceutical companies in the context of the reimbursement application procedure for combination therapies. This follows a prioritisation statement adopted by the UK Competition and Markets Authority (CMA) in 2023 on the same issue and long-standing demands from the Belgian pharmaceutical industry.[1] In…